Merete Lund Mægbæk

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Standard

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi. / Steffensen, Maria Charlotte; Mægbæk, Merete Lund; Laurberg, Peter; Andersen, Marianne; Kistorp, Caroline; Nørrelund, Helene; Dal, Jakob; Jørgensen, Jens Otto Lunde.

In: Ugeskrift for Laeger, Vol. 176, No. 1, 06.01.2014, p. 58-60.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{86bd46fcd3d046bebf7664dcc86ce3bf,
title = "Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktin{\ae}mi",
abstract = "Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.",
author = "Steffensen, {Maria Charlotte} and M{\ae}gb{\ae}k, {Merete Lund} and Peter Laurberg and Marianne Andersen and Caroline Kistorp and Helene N{\o}rrelund and Jakob Dal and J{\o}rgensen, {Jens Otto Lunde}",
year = "2014",
month = jan,
day = "6",
language = "Dansk",
volume = "176",
pages = "58--60",
journal = "Ugeskrift for L{\ae}ger ",
issn = "0041-5782",
publisher = "Den Almindelige Danske L{\ae}geforening",
number = "1",

}

RIS

TY - JOUR

T1 - Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

AU - Steffensen, Maria Charlotte

AU - Mægbæk, Merete Lund

AU - Laurberg, Peter

AU - Andersen, Marianne

AU - Kistorp, Caroline

AU - Nørrelund, Helene

AU - Dal, Jakob

AU - Jørgensen, Jens Otto Lunde

PY - 2014/1/6

Y1 - 2014/1/6

N2 - Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

AB - Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

M3 - Review

C2 - 24629610

VL - 176

SP - 58

EP - 60

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

SN - 0041-5782

IS - 1

ER -